早盘，港股市场创新药集体大跌，其抗肿瘤、辅助生殖、创新药、CXO板块跌幅都一度超过6%。A股 创新药也跟随集体走弱，百济神州、益方生物跌超10%，新诺威、华海药业、微芯生物、荣昌生物、药 明康德等多股跌超6%。消息面上，市场传来一则不利消息。不过，研究机构却集体强CALL，认为此次 杀跌是买入良机。并认为A股和港股医药板块的走势还远没有结束，上涨主升浪还有望中长期持续。消 息面上，刷屏各大投资圈的信息指出，特朗普政府正在考虑对来自中国的药品实施严格限制，包括一项 行政命令草案，该草案可能会扰动中国发明的实验性疗法，并可能会影响美国的制药行业，并限制仿制 药和先进疗法的可用性。不过，值得注意的是，白宫方面表示，没有"积极考虑"该草案。（券商中国） ...

Group 1 - The innovative drug concept stocks opened lower on September 11, with companies like BeiGene and Tigermed experiencing declines of over 10% [1] - WuXi AppTec fell by more than 7%, while other companies such as HengRui Medicine, Yuandong Bio, Huahai Pharmaceutical, and Saili Medical saw declines exceeding 5% [1] - After half an hour of trading, BeiGene's decline narrowed to below 7%, resulting in a market value loss of over 30 billion yuan compared to the previous trading day [1]

Market Reaction - On September 11, the innovative drug concept stocks opened lower, with companies like BeiGene and Tigermed experiencing declines of over 10% [1] - WuXi AppTec fell over 7%, while other companies such as HengRui Medicine, Yuandong Bio, Huahai Pharmaceutical, and Sihuan Pharmaceutical saw declines exceeding 5% [1] - After half an hour of trading, BeiGene's decline narrowed to below 7%, but its latest market value evaporated by over 30 billion CNY compared to the previous trading day [1]

9月11日早盘，创新药概念股低开，百济神州、泰格医药一度跌超10%，盘中最低价278.9元/股；药明康 德跌超7%，恒瑞医药，苑东生物、华海药业、塞力医疗等多股跌超5%。开盘半小时后，百济神州跌幅 缩窄至7%以下，较前一交易日，其A股最新市值蒸发超300亿。 （文章来源：第一财经） ...

Group 1 - Dematech won a 900 million yuan overseas smart logistics project from a well-known e-commerce giant in Latin America, focusing on intelligent logistics cross-belt sorting systems and related services [1] - Kang En Bei received approval for the registration of short-term financing bonds and medium-term notes, with a total registration amount of 1 billion yuan, valid for two years [1][2] - Zhi Xiang Jin Tai's GR1803 injection for systemic lupus erythematosus clinical trial has been approved by the National Medical Products Administration [2] Group 2 - Jin Da Wei's subsidiary received approval for a veterinary drug product, pyridone, valid from September 3, 2025, to September 2, 2030 [4] - Fu Li Wang's subsidiary plans to invest 500 million yuan in a high-end wire material project, focusing on high-strength prestressed steel strands for various applications [5] - He Li Biological's subsidiary's Class III medical device registration application has been accepted, focusing on natural bone repair materials [12] Group 3 - Lin Yang Energy won a 244 million yuan metering equipment project from Southern Power Grid, expected to positively impact its 2025 and 2026 performance [20] - Sanxia Water plans to absorb its wholly-owned subsidiary, Chongqing Changdian United Energy, with all assets and liabilities to be inherited by Sanxia Water [13] - Tian Cheng Technology canceled the use of 91 million yuan of raised funds for permanent working capital, ensuring no impact on the normal operation of investment projects [24] Group 4 - Baosteel received approval to publicly issue bonds totaling 20 billion yuan to professional investors, valid for 24 months [52] - Tian Kang Biological reported a 10.15% year-on-year increase in pig sales in August, with a total of 263,800 pigs sold [53] - Xinjiang Construction won multiple major projects totaling 4.506 billion yuan, including a 2.4 billion yuan photovoltaic hydrogen synthesis project [18]

Market Performance - The pharmaceutical sector experienced a decline of -1.91% on September 9, 2025, underperforming the CSI 300 index by 1.21 percentage points, ranking 28th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, pharmaceutical distribution (-0.52%), blood products (-0.62%), and in vitro diagnostics (-0.73%) performed relatively better, while medical R&D outsourcing (-3.63%), medical devices (-2.47%), and medical consumables (-2.06%) lagged behind [1] - Top three gainers included Rongchang Bio (+11.92%), Hehua Co. (+10.07%), and Zhend Medical (+10.00%), while the largest decliners were Yifang Bio (-11.74%), Huahai Pharmaceutical (-10.00%), and Chenxin Pharmaceutical (-8.42%) [1] Industry News - BMS announced positive results from the Phase II clinical trial of Pumitamig, a bispecific antibody developed in collaboration with BioNTech for the treatment of extensive-stage small cell lung cancer (ES-SCLC), showing a confirmed objective response rate (cORR) of 76.3% and a disease control rate (DCR) of 100% [2] - Pumitamig targets PD-L1 and VEGF-A, designed to restore the function of effector T cells in the tumor microenvironment while locally neutralizing the effects of VEGF-A [2] Company News - Heng Rui Medicine (600276) announced that its subsidiary Chengdu Shengdi Pharmaceutical received approval from the National Medical Products Administration for its product, Eicosapentaenoic Acid Ethyl Ester Soft Capsules, to lower triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL) [3] - Taiji Group (600129) reported that its subsidiary Fuling Pharmaceutical Factory received a clinical trial approval notice for Semaglutide injection for the treatment of type 2 diabetes [3] - Huahai Pharmaceutical (600521) disclosed that its subsidiary Huahai Jiancheng underwent a pre-approval inspection by the FDA from July 14 to 18, 2025, covering the overall quality management system and the active pharmaceutical ingredient Gabapentin, which met the CGMP requirements [3] - Dongfang Bio (688298) announced that its subsidiary Laihe Bio obtained a Class III medical device registration certificate for its influenza virus antigen detection kit (colloidal gold method), enhancing the company's product portfolio in the respiratory joint detection field [3]

Report Industry Investment Rating No relevant information provided. Core Viewpoints - Global inflation showed initial signs of rising in August. China's economic data in July still had resilience, but domestic monthly economic data faced pressure. The government emphasized measures to stabilize the real - estate market, expand consumption, and increase investment. China's August exports and imports had different trends, and September exports might improve due to a low base. The A - share market on September 9 was in an adjustment state. In the US, the manufacturing index contracted, and employment data was worse than expected. The Fed is expected to restart the easing cycle, and there are concerns about its credibility crisis. In Japan, policy uncertainty increased, leading to a sell - off of long - term government bonds. For commodities, different sectors have different outlooks, and it is recommended to go long on industrial products and precious metals at low prices [2][3][4][5]. Summary by Related Catalogs Market Analysis - In August, global inflation began to rise. China's July exports increased year - on - year, supported by a low base and the "rush - to - export" effect. Financial data showed excessive money supply but weak financing and loan data. Investment data faced pressure. In August, China's exports grew by 4.4% year - on - year, a 2.8 - percentage - point decrease from July, mainly affected by a high base and tariffs. Exports to the US weakened, while those to emerging economies remained strong. Imports grew by 1.3% year - on - year, a 2.8 - percentage - point slowdown, dragged down by commodity imports. On September 9, the A - share market adjusted, with the ChiNext Index falling more than 3% in the afternoon. In the US, the August ISM manufacturing index contracted for the sixth consecutive month, and employment data was worse than expected [2]. Fed Policy - Powell's speech at the global central bank meeting on August 22 turned dovish, indicating a possible policy adjustment. The Fed is expected to restart the easing cycle as August's employment data was disappointing. There is a growing credibility crisis at the Fed, with criticism from Trump and the US Treasury Secretary. Trump has announced potential candidates for the next Fed chair, and the nomination of Milan is to be voted on [3]. Commodity Analysis - Domestically, the black and new - energy metal sectors are most sensitive to the supply side. Overseas inflation expectations can focus on precious metals and agricultural products. The black sector is still affected by downstream demand expectations, and the supply constraint in the non - ferrous sector persists. The energy supply is expected to be relatively loose in the medium term. In the chemical sector, there is "anti - involution" space for some products. Agricultural products are driven by tariffs and inflation expectations but need fundamental support. Precious metals are a good long - term investment opportunity as the Fed is about to restart the interest - rate cut cycle [4]. Strategy - For commodities and stock index futures, it is recommended to go long on industrial products and precious metals at low prices [5]. Key News - On September 9, the A - share market adjusted, with the ChiNext Index falling. Gold, real - estate, and bank stocks performed well, while semiconductor and innovation - drug stocks declined. An explosion in Doha, Qatar, led to a short - term rise in international oil prices. The US 2025 non - farm employment benchmark change was worse than expected. The Senate will vote on Milan's nomination as a Fed governor, and the FOMC is expected to cut interest rates in September [7].

Group 1 - The company Zhejiang Huahai Pharmaceutical Co., Ltd. announced that its subsidiary, Zhejiang Huahai Jiancheng Pharmaceutical Co., Ltd., passed the FDA pre-approval inspection, confirming compliance with CGMP requirements [1][2] - The inspection took place from July 14 to July 18, 2025, covering the overall quality management system and the active pharmaceutical ingredient Gabapentin [1][2] - Gabapentin is a widely prescribed medication for epilepsy and neuropathic pain, indicating its significant role in the global pharmaceutical market [1][2] Group 2 - The successful FDA inspection enhances the company's core competitiveness and supports its ongoing international market expansion [2] - The company has registered its Gabapentin products in multiple countries, including Europe, the United States, and South Korea, ensuring a stable market presence [1][2]

Group 1 - The core point of the announcement is that Zhejiang Huahai Pharmaceutical Co., Ltd.'s subsidiary, Zhejiang Huahai Jiancheng Pharmaceutical Co., Ltd., successfully passed the FDA's pre-approval inspection, indicating compliance with the FDA's quality management system requirements [1][2] - The inspection took place from July 14 to July 18, 2025, covering the overall quality management system of the factory and the active pharmaceutical ingredient Gabapentin [1] - The inspection result was classified as NAI (No Action Indicated), which signifies zero defects in the inspection [1] Group 2 - The successful FDA inspection enhances the company's ability to expand in international markets and positively impacts its core competitiveness and sustainable development [2] - Gabapentin, primarily used for treating epilepsy and neuropathic pain, is one of the most prescribed drugs globally, indicating its significant role in the pharmaceutical market [1][2] - The company's Gabapentin active pharmaceutical ingredient is already registered in multiple countries, including Europe, the United States, and South Korea [1]

Group 1 - The chemical pharmaceutical sector experienced a downturn on September 9, with several companies facing significant declines [1] - Huahai Pharmaceutical hit the daily limit down, indicating a severe drop in stock price [1] - Other companies such as Yifang Bio-U, Chenxin Pharmaceutical, Jiankai Technology, Huana Pharmaceutical, Lifang Pharmaceutical, and Baili Tianheng also saw declines in their stock prices [1]